期刊文献+

^(125)I-VIP的制备及其与SGC7901人胃腺癌细胞受体体外结合特性研究 被引量:4

The preparation of 125 I VIP and its characters of binding to the receptors of SGC7901 cell line derived from human gastric adenocarcinoma
暂未订购
导出
摘要 目的探讨高比活度125I血管活性肠肽(VIP)的制备及其与人SGC7901胃腺癌细胞受体体外结合特性。方法125IVIP采用氯胺T法标记,SephadexG50柱层析分离纯化,硅胶60F254薄板层析检测。125IVIP与SGC7901细胞进行体外时间温度结合实验、可逆结合实验、饱和结合实验和竞争结合实验,通过125IUdR参入实验与cAMP生成实验评价VIP对SGC7901细胞的生物效应。结果125I标记率为738%,125IVIP比活度为182TBq/mmol,放射化学纯度(RCP)为982%,-80℃贮存48天后RCP仍有963%;125IVIP与SGC7901细胞结合具有温度与时间依赖性、可饱和性、可逆性及特异性,Scatchard作图提示SGC7901细胞含有高低亲和力两种VIP受体,Kd分别为0230与2788nmol/L,Bmax为0120与5607pmol/106细胞;VIP以剂量依赖方式促进SGC7901细胞cAMP产生和DNA的合成。结论制备的125IVIP符合作为VIP受体特异性配体的标准,碘标记VIP并不改变与其受体的结合活性;首次证实SGC790? Purpose To investigate the preparation of 125 I vasoactive intestinal peptide (VIP) and its characters of binding to SGC7901 cell receptors Methods VIP was labeled with Na 125 I using chloramine T method, then isolated by sephadex G 50 column chromatography and examined by silica 60F 254 thin layer chromatography (TLC) The tests of time temperature binding, reversible binding, saturable binding and competition binding between SGC7901 cells and 125 I VIP were carried out Results The labelling rate of 125 I was 73 8%, the specific activity of 125 I VIP was 18 2TBq/mmol, the radiochemical purity was over 98 2% and remained 96 3% after a 48 days' storage at -80℃ The results demonstrated that the binding of 125 I VIP to SGC7901 cells possessed the reversibility, specificity, saturability, and was time temperature dependent It was confirmed that VIP promoted the production of cAMP and the synthesis of DNA in SGC7901 cells dose dependently Scatchard plotting suggested that SGC7901 cells contained two types of VIP receptors, high affinity receptor and low affinity receptor The concentrations of Kd and B max were 0 230nmol/L and 0 120pmol/10 6 cells for high affinity receptor, 2 788nmol/L and 5 607pmol/10 6 cells for low affinity receptor Conclusions The present study indicates that the labeled 125 I VIP can be used for receptor analysis and the iodination of VIP does not change its binding to VIP receptor We are the first who have confirmed that the SGC7901 cell line expresses VIP receptors of high density and affinity
出处 《中华核医学杂志》 CAS CSCD 北大核心 1998年第2期73-76,共4页 Chinese Journal of Nuclear Medicine
基金 国家自然科学基金
关键词 胃癌 腺癌 血管活性肠肽 碘125 Vasoactive intestinal peptide Iodine radioisotopes Isotope labeling Receptor Stomach neoplasms
  • 相关文献

同被引文献18

  • 1安明榜,吕宝璋.rIL-2的^(125)Ⅰ标记及淋巴细胞IL-2受体的鉴定[J].中华核医学杂志,1996,16(3):157-158. 被引量:1
  • 2邓尚平 谭天秩 等.A14或A19-[^125I]-胰岛素的制备及其意义[J].四川医学院学报,1981,12(4):275-281.
  • 3李前伟,中华核医学杂志,1998年,18卷,2期,73页
  • 4Fraser J K,Blood,1988年,71卷,1期,104页
  • 5Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors[J]. Cancer Res, 1994, 54(3): 690-700.
  • 6Reubi J C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications[J]. Ann N Y Acad Sci, 2000,9:21: 1-25.
  • 7Bhargava S, Licha K, Knaute T, et al. A complete substitutional analysis of VIP for better tumor imaging properties[J]. J Mol Recognit, 2002, 15(3) : 145 - 153.
  • 8Thakur M L, Aruva M R, Gariepy J, et al. PET imaging of oncogene over-expression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog[J]. J Nucl Med, 2004, 45(8) : 1381 - 1389.
  • 9Virgolini I, Raderer M, Kurtaran A, et al. ^123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with ad-and endocrine tumors of the gastrointestinal tract [ J ]. Nucl Med Biol, 1996, 23(6) : 685 - 692.
  • 10Raderer M, Kurtaran A, Yang Q, et al. lodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer [ J ]. J Nucl Med, 1998, 39(9): 1570-1575.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部